<DOC>
	<DOCNO>NCT02415348</DOCNO>
	<brief_summary>This study design determine Fibroscan ( Echosens , Paris ) , non-invasive , ultrasound-based device use estimate fibrosis patient chronic liver disease , interfere implanted cardiac pacemaker and/or implantable cardioverter-defibrillators . Recruitment consist total 200 outpatient undergoing routine pacemaker interrogation teaching-hospital pacemaker clinic .</brief_summary>
	<brief_title>The Use Fibroscan Assess Liver Fibrosis Patients With Cardiac Pacemakers</brief_title>
	<detailed_description>Assessment liver fibrosis patient chronic liver disease provide stag prognostic information critical establishing treatment priority . The gold standard evaluation liver fibrosis hamper invasive nature liver biopsy . FibroScan non-invasive alternative extensively validate chronic hepatitis C , chronic hepatitis B , alcoholic liver disease , non- alcoholic fatty liver disease patient . To avoid unknown risk potential interaction , manufacturer advise use device patient active implantable medical device include cardiac pacemaker and/or implantable cardioverter-defibrillators ( ICD ) . Review literature show two population specifically exclude previously report study . At time writing , specific report demonstrate either safety potential harm FibroScan patient pacemaker/ICD . Given proven benefit FibroScan chronic liver disease current policy exclude patient pacemaker/ICD clinical practice , study aim formally evaluate safe use FibroScan population within control environment pacemaker lab .</detailed_description>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<criteria>Any outpatient undergoing routine pacemaker interrogation pacemaker clinic Pregnancy BMI &gt; 35 Person active implantable medical device cardiac pacemaker and/or ICD Person unable tolerate lie flat FibroScan examination .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>